This is a well-documented risk factor in AML, as the presence of mutations in FLT3 is often associated with reduced OS, particularly in NPM1-mutated patients, and improves risk stratification in patients without cytogenetic abnormalities26. Here, NPM1 is linked to acute myeloid leukemia.